Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11368285 | 0.81 | LMNA (0.57) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1813226 | 0.80 | KCNH2 (0.46) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL12655358 | 0.80 | KCNH2 (0.50) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL31185337 | 0.80 | KCNH2 (0.46) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL8313978 | 0.80 | SIGMAR1 (0.60) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL11361449 | 0.78 | MEN1 (0.52) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL934263 | 0.77 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL350330 | 0.77 | OPRK1 (0.47) | MEN1KMT2ANPSR1OPRK1ENPP2 | |
| SCHEMBL3970912 | 0.77 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4814264 | 0.77 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| EP-1423391-B8 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1423391-B1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2005-03-10 | — | — | US | disclosed |
| EP-1423391-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | CTSK, CTSS, CTSZ | MEN1 4225/4885KMT2A 4486/4885NPSR1 1309/4885 |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | CTSK, CTSS, CTSZ | MEN1 4225/4885KMT2A 4486/4885NPSR1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.